7802: Six Food vs One Food Eosinophilic Esophagitis Elimination Diet followed by Swallowed Glucocorticoid Trial - SOFEED - ENROLLMENT COMPLETED

Status: Closed

The purpose of this interventional study is to test and compare the effectiveness of two elimination diets—the 1-food elimination diet (1FED; milk only) and the 6-food elimination diet (6FED; milk, egg, wheat, soy, tree nut/peanuts, and fish/shellfish).  The study will also test the effectiveness of swallowed glucocorticoid therapy in some of the study participants for whom diet therapy was not effective.

For Diseases

  • Eosinophilic Esophagitis (EoE)


People with a diagnosis of eosinophilic esophagitis (EoE) experience various symptoms in addition to microscopic damage to their digestive tract. There is no known cure for EoE, although effective treatments exist. This study aims to test dietary therapies for EoE to see how effective they are and to monitor participants’ symptoms and quality of life while participating in the study. The study will also test the effectiveness of swallowed glucocorticoid therapy in some of the participants for whom dietary therapy was not effective. We aim to identify the best dietary approach, with a focus on minimal food eliminations, and to understand how to predict responsiveness.

This is an interventional study of 120 individuals with EoE between the ages of 18 and 60 years of age. Participants will be seen at one of the clinical sites around the United States. Participants will be in the study for approximately 10 weeks to 17 weeks, depending on how they respond to the dietary therapy. Participants will be randomly assigned to one of the two elimination diet therapies, the 1FED or the 6FED. If a participant’s EoE is in remission after receiving 6 weeks of 1FED or 6FED therapy, the participant will be done with study participation. If a participant’s EoE is still active, the participant will continue on to either 6FED therapy (if they were previously on 1FED) or swallowed glucocorticoid therapy (if they were previously on 6FED) for 6 weeks.

During the study, you will be asked to:

  • Keep a log of what you eat for three days, complete dietary questionnaires, and talk to a dietitian about what you eat
  • Have a physical exam
  • Have vital signs (heart rate, blood pressure, temperature, breathing rate) measured
  • Fill out feedback forms about your symptoms and quality of life
  • Give blood (1 to 2 teaspoons at a time)
  • Have a pregnancy test (female participants only)
  • Have skin prick and skin patch allergy testing
  • Follow/take the assigned study therapy (1FED, 6FED, or swallowed glucocorticoids)

As part of standard of care (your normal care) you will:

  • Have an endoscopy
  • Have a biopsy (As part of standard of care endoscopy, the doctor will take small sections of your esophagus tissue (biopsies) to check cells.)

Targeted Enrollment

To be eligible to participate, you must:

  • Be male or female age 18-60
  • Be diagnosed with:Eosinophilic esophagitis (EoE)
  • Have symptoms of EoE
  • Have esophageal eosinophilia (eosinophils in your esophagus)

You are not eligible to participate if:

  • You have been treated with topical swallowed steroids within the last 2 months or systemic steroids within the last 3 months
  • You have eosinophils in other parts of your GI tract (for example, the stomach or colon)
  • You have been diagnosed with a GI malabsorption disorder (Inflammatory Bowel Disease, Crohn’s Disease) or Celiac Disease
  • You are currently on dietary therapy strictly avoiding milk or on a 6FED
  • You currently have H. pylori gastritis or a parasitic infection
  • You have a history of anaphylaxis (a severe allergic reaction) to milk
  • You have used investigational drugs (i.e. participated in a drug study) within 4 weeks prior to starting the study
  • You are receiving any medications that are not allowed while on the study
  • You are on immunotherapy for pollen (if not on maintenance therapy) or IgE-mediated food allergy
  • You have other medical conditions or findings that the doctor feels make participation in the study unsafe

In order to participate in a study, you must personally contact the study coordinator of any of the participating institutions by phone or by e-mail.


University of California, San Diego
Contact: Lea Jacinto, Clinical Research Coordinator
Phone: 858-246-2144
Email: ljacinto@ucsd.edu


University of Colorado, Aurora
Contact: Jonathon Cahoon, Clinical Research Coordinator
Phone: 303-724-8974
Email: jonathon.cahoon@ucdenver.edu


Northwestern University, Chicago
Contact: Angelika Zalewski
Phone: 312-695-4054
Email: angelika.zalewski@northwestern.edu


Tufts University, Boston
Contact: Tess Brown, Clinical Research Coordinator
Phone: 617-636-4941
Email: tbrown6@tuftsmedicalcenter.org


Mayo Clinic, Rochester
Contact: Debra Geno
Phone: 507-538-0367
Email: geno.debra@mayo.org

New York

Icahn School of Medicine Mount Sinai, New York
Contact: Mirna Chehade, MD, MPH , Principal Investigator
Phone: 212-241-4880
Fax: 212-426-1902 
Email: mirna.chehade@mssm.edu

North Carolina

University of North Carolina, Chapel Hill
Contact: Shiyan Shoyoye, Clinical Research Coordinator
Phone: 919-843-0688
Email: shoyoye@med.unc.edu


Cincinnati Children's Hospital Medical Center (CCHMC), Cincinnati
Contact: Heidi Poppendeck
Phone: 513-803-3078
Email: heidi.poppendeck@cchmc.org


University of Pennsylvania, Philadelphia
Contact: Maureen DeMarshall
Phone: 215-349-8546
Email: demarshm@mail.med.upenn.edu

Children’s Hospital of Philadelphia, Philadelphia
Contact: Deirdre Burke
Phone: 267-426-8603
Email: Burked2@email.chop.edu


University of Utah, Salt Lake City
Contact: Alyssa Mills
Phone: 801-587-3608
Email: alyssa.mills@hsc.utah.edu

Please Note: The Rare Diseases Clinical Research Network will make every effort to enroll all the patients we can, but we cannot make any guarantees that we will be able to enroll everyone in a particular study who wants to participate.